A comparison of machine learning techniques for classification of HIV patients with antiretroviral therapy-induced mitochondrial toxicity from those without mitochondrial toxicity.
Antiretroviral therapy
Classification
Dimension reduction
HIV/AIDS
Machine learning
Mitochondrial toxicity
Journal
BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545
Informations de publication
Date de publication:
27 11 2019
27 11 2019
Historique:
received:
03
04
2019
accepted:
10
10
2019
entrez:
29
11
2019
pubmed:
30
11
2019
medline:
6
10
2020
Statut:
epublish
Résumé
Antiretroviral therapy (ART) has significantly reduced HIV-related morbidity and mortality. However, therapeutic benefit of ART is often limited by delayed drug-associated toxicity. Nucleoside reverse transcriptase inhibitors (NRTIs) are the backbone of ART regimens. NRTIs compete with endogenous deoxyribonucleotide triphosphates (dNTPs) in incorporation into elongating DNA chain resulting in their cytotoxic or antiviral effect. Thus, the efficacy of NRTIs could be affected by direct competition with endogenous dNTPs and/or feedback inhibition of their metabolic enzymes. In this paper, we assessed whether the levels of ribonucleotides (RN) and dNTP pool sizes can be used as biomarkers in distinguishing between HIV-infected patients with ART-induced mitochondrial toxicity and HIV-infected patients without toxicity. We used data collected through a case-control study from 50 subjects. Cases were defined as HIV-infected individuals with clinical and/or laboratory evidence of mitochondrial toxicity. Each case was age, gender, and race matched with an HIV-positive without evidence of toxicity. We used a range of machine learning procedures to distinguish between patients with and without toxicity. Using resampling methods like Monte Carlo k-fold cross validation, we compared the accuracy of several machine learning algorithms applied to our data. We used the algorithm with highest classification accuracy rate in evaluating the diagnostic performance of 12 RN and 14 dNTP pool sizes as biomarkers of mitochondrial toxicity. We used eight classification algorithms to assess the diagnostic performance of RN and dNTP pool sizes distinguishing HIV patients with and without NRTI-associated mitochondrial toxicity. The algorithms resulted in cross-validated classification rates of 0.65-0.76 for dNTP and 0.72-0.83 for RN, following reduction of the dimensionality of the input data. The reduction of input variables improved the classification performance of the algorithms, with the most pronounced improvement for RN. Complex tree-based methods worked the best for both the deoxyribose dataset (Random Forest) and the ribose dataset (Classification Tree and AdaBoost), but it is worth noting that simple methods such as Linear Discriminant Analysis and Logistic Regression were very competitive in terms of classification performance. Our finding of changes in RN and dNTP pools in participants with mitochondrial toxicity validates the importance of dNTP pools in mitochondrial function. Hence, levels of RN and dNTP pools can be used as biomarkers of ART-induced mitochondrial toxicity.
Sections du résumé
BACKGROUND
Antiretroviral therapy (ART) has significantly reduced HIV-related morbidity and mortality. However, therapeutic benefit of ART is often limited by delayed drug-associated toxicity. Nucleoside reverse transcriptase inhibitors (NRTIs) are the backbone of ART regimens. NRTIs compete with endogenous deoxyribonucleotide triphosphates (dNTPs) in incorporation into elongating DNA chain resulting in their cytotoxic or antiviral effect. Thus, the efficacy of NRTIs could be affected by direct competition with endogenous dNTPs and/or feedback inhibition of their metabolic enzymes. In this paper, we assessed whether the levels of ribonucleotides (RN) and dNTP pool sizes can be used as biomarkers in distinguishing between HIV-infected patients with ART-induced mitochondrial toxicity and HIV-infected patients without toxicity.
METHODS
We used data collected through a case-control study from 50 subjects. Cases were defined as HIV-infected individuals with clinical and/or laboratory evidence of mitochondrial toxicity. Each case was age, gender, and race matched with an HIV-positive without evidence of toxicity. We used a range of machine learning procedures to distinguish between patients with and without toxicity. Using resampling methods like Monte Carlo k-fold cross validation, we compared the accuracy of several machine learning algorithms applied to our data. We used the algorithm with highest classification accuracy rate in evaluating the diagnostic performance of 12 RN and 14 dNTP pool sizes as biomarkers of mitochondrial toxicity.
RESULTS
We used eight classification algorithms to assess the diagnostic performance of RN and dNTP pool sizes distinguishing HIV patients with and without NRTI-associated mitochondrial toxicity. The algorithms resulted in cross-validated classification rates of 0.65-0.76 for dNTP and 0.72-0.83 for RN, following reduction of the dimensionality of the input data. The reduction of input variables improved the classification performance of the algorithms, with the most pronounced improvement for RN. Complex tree-based methods worked the best for both the deoxyribose dataset (Random Forest) and the ribose dataset (Classification Tree and AdaBoost), but it is worth noting that simple methods such as Linear Discriminant Analysis and Logistic Regression were very competitive in terms of classification performance.
CONCLUSIONS
Our finding of changes in RN and dNTP pools in participants with mitochondrial toxicity validates the importance of dNTP pools in mitochondrial function. Hence, levels of RN and dNTP pools can be used as biomarkers of ART-induced mitochondrial toxicity.
Identifiants
pubmed: 31775643
doi: 10.1186/s12874-019-0848-z
pii: 10.1186/s12874-019-0848-z
pmc: PMC6882363
doi:
Substances chimiques
Anti-Retroviral Agents
0
Biomarkers
0
Deoxyribonucleotides
0
Dideoxynucleotides
0
Ribonucleotides
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
216Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI074404
Pays : United States
Références
J Biol Chem. 2003 Nov 7;278(45):43893-6
pubmed: 13679382
Annu Rev Biochem. 1988;57:349-74
pubmed: 3052277
Biochim Biophys Acta. 2000 Mar 6;1474(1):5-12
pubmed: 10699484
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):263-71
pubmed: 26871881
J Mol Cell Cardiol. 2010 Nov;49(5):746-52
pubmed: 20736017
FASEB J. 2007 Aug;21(10):2294-303
pubmed: 17403938
Eur J Cancer. 1998 May;34(6):921-6
pubmed: 9797708
Hepatology. 2010 Jul;52(1):115-25
pubmed: 20564379
Antivir Ther. 2004 Feb;9(1):47-55
pubmed: 15040536
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S73-9
pubmed: 14986278
Pharmacol Ther. 2000 Aug-Sep;87(2-3):189-98
pubmed: 11008000
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):4990-5
pubmed: 15784738
Clin Infect Dis. 2005 Sep 15;41(6):883-90
pubmed: 16107990
FASEB J. 2006 Jul;20(9):1300-14
pubmed: 16816105
Clin Pharmacol Ther. 2014 Jul;96(1):110-20
pubmed: 24637942
Toxicol Pathol. 2014 Jul;42(5):811-22
pubmed: 24067671
AIDS. 1998 Oct 1;12(14):1735-44
pubmed: 9792373
Mol Cell Biochem. 1994 Nov 9;140(1):1-22
pubmed: 7877593
Clin Ther. 2000 Aug;22(8):911-36; discussion 898
pubmed: 10972629
Mutat Res. 1994 Aug;318(1):1-64
pubmed: 7519315